Bio-Techne ( ) has shared an announcement. On September 23, 2026, Bio-Techne shareholders approved the Agreement and Plan of Merger under which Merck KGaA, Darmstadt, Germany will ...
Bio-Techne, a Minneapolis-based provider of life sciences tools, reagents, and diagnostic products, has announced that its shareholders have approved the company's proposed acquisition by Merck KGaA, ...
Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...
Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.
StockStory.org on MSN
3 reasons to sell TECH and 1 stock to buy instead
Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now ...
Located in one of Europe's leading centers for academic research and innovation, the Düsseldorf Customer Experience Center ...
Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...
View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.
Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results